#BEGIN_DRUGCARD DB00987

# AHFS_Codes:
10:00.00

# ATC_Codes:
L01BC01

# Absorption:
Less than 20% of the orally administered dose is absorbed from the gastrointestinal tract.

# Biotransformation:
Hepatic.

# Brand_Mixtures:
Not Available

# Brand_Names:
AR3
Alexan
Arabitin
Arafcyt
Cytarbel
Cytosar
Cytosar-U
Depocyt
Depocyt (liposomal)
Erpalfa
Iretin
Spongocytidine
Tarabine
Udicil

# CAS_Registry_Number:
147-94-4

# ChEBI_ID:
28680

# Chemical_Formula:
C9H13N3O5

# Chemical_IUPAC_Name:
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2167883

# Description:
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

# Dosage_Forms:
Powder, for solution	Intrathecal
Solution	Intrathecal
Suspension	Intrathecal

# Drug_Category:
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Immunosuppressive Agents

# Drug_Interactions:
Digoxin	The antineoplasic agent decreases the effect of digoxin
Trastuzumab	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-2.8

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Freely soluble

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Cytarabine

# HET_ID:
AR3

# Half_Life:
10 minutes

# InChI_Identifier:
InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1

# InChI_Key:
InChIKey=UHDGCWIWMRVCDJ-CCXZUQQUSA-N

# Indication:
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

# KEGG_Compound_ID:
C02961

# KEGG_Drug_ID:
D00168

# LIMS_Drug_ID:
987

# Mechanism_Of_Action:
Cytarabine acts through direct DNA damage and incorporation into DNA. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells from the G1 phase to the S-phase. Although the mechanism of action is not completely understood, it appears that cytarabine acts through the inhibition of DNA polymerase. A limited, but significant, incorporation of cytarabine into both DNA and RNA has also been reported.

# Melting_Point:
212.5 Â°C

# Molecular_Weight_Avg:
243.2166

# Molecular_Weight_Mono:
243.085520541

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
8ICK

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA449177

# Pharmacology:
Cytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Cytarabine is metabolized intracellularly into its active triphosphate form (cytosine arabinoside triphosphate). This metabolite then damages DNA by multiple mechanisms, including the inhibition of alpha-DNA polymerase, inhibition of DNA repair through an effect on beta-DNA polymerase, and incorporation into DNA. The latter mechanism is probably the most important. Cytotoxicity is highly specific for the S phase of the cell cycle.

# Predicted_LogP_Hydrophobicity:
-2.2

# Predicted_LogS:
-0.74

# Predicted_Water_Solubility:
4.38e+01 g/l

# Primary_Accession_No:
DB00987

# Protein_Binding:
13%

# PubChem_Compound_ID:
6253

# PubChem_Substance_ID:
46505879

# RxList_Link:
http://www.rxlist.com/cgi/generic3/cytarabine.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00499

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Ara-C
AraC
Arabinocytidine
Arabinofuranosylcytosine
Arabinosylcytosine
Aracytidine
Aracytin
Aracytine
Beta-cytosine arabinoside
Citarabina [INN-Spanish]
Cytarabin
Cytarabina
Cytarabinoside
Cytarabinum [INN-Latin]
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine beta-D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-beta-D-arabinofuranoside
Cytosine-beta-arabinoside
beta-Arabinosylcytosine
beta-D-Arabinosylcytosine
cytarabine liposome injection

# Synthesis_Reference:
Not Available

# Toxicity:
Cytarabine syndrome may develop - it is characterized by fever, myalgia, bone pain, occasionally chest pain, maculopapular rash, conjunctivitis, and malaise.

# Update_Date:
2013-02-08 16:19:48 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Cytarabine

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
NT5E

# Phase_1_Metabolizing_Enzyme_1_ID:
1830

# Phase_1_Metabolizing_Enzyme_1_Name:
5'-nucleotidase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>5'-nucleotidase precursor
MCPRAARAPATLLLALGAVLWPAAGAWELTILHTNDVHSRLEQTSEDSSKCVNASRCMGG
VARLFTKVQQIRRAEPNVLLLDAGDQYQGTIWFTVYKGAEVAHFMNALRYDAMALGNHEF
DNGVEGLIEPLLKEAKFPILSANIKAKGPLASQISGLYLPYKVLPVGDEVVGIVGYTSKE
TPFLSNPGTNLVFEDEITALQPEVDKLKTLNVNKIIALGHSGFEMDKLIAQKVRGVDVVV
GGHSNTFLYTGNPPSKEVPAGKYPFIVTSDDGRKVPVVQAYAFGKYLGYLKIEFDERGNV
ISSHGNPILLNSSIPEDPSIKADINKWRIKLDNYSTQELGKTIVYLDGSSQSCRFRECNM
GNLICDAMINNNLRHTDEMFWNHVSMCILNGGGIRSPIDERNNGTITWENLAAVLPFGGT
FDLVQLKGSTLKKAFEHSVHRYGQSTGEFLQVGGIHVVYDLSRKPGDRVVKLDVLCTKCR
VPSYDPLKMDEVYKVILPNFLANGGDGFQMIKDELLRHDSGDQDINVVSTYISKMKVIYP
AVEGRIKFSTGSHCHGSFSLIFLSLWAVIFVLYQ

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P21589

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CDA

# Phase_1_Metabolizing_Enzyme_2_ID:
4211

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytidine deaminase

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytidine deaminase
MAQKRPACTLKPECVQQLLVCSQEAKKSAYCPYSHFPVGAALLTQEGRIFKGCNIENACY
PLGICAERTAIQKAVSEGYKDFRAIAIASDMQDDFISPCGACRQVMREFGTNWPVYMTKP
DGTYIVMTVQELLPSSFGPEDLQKTQ

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P32320

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_3_ID:
4512

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_4_Gene_Name:
DCK

# Phase_1_Metabolizing_Enzyme_4_ID:
4773

# Phase_1_Metabolizing_Enzyme_4_Name:
Deoxycytidine kinase

# Phase_1_Metabolizing_Enzyme_4_Protein_Sequence:
>Deoxycytidine kinase
MATPPKRSCPSFSASSEGTRIKKISIEGNIAAGKSTFVNILKQLCEDWEVVPEPVARWCN
VQSTQDEFEELTMSQKNGGNVLQMMYEKPERWSFTFQTYACLSRIRAQLASLNGKLKDAE
KPVLFFERSVYSDRYIFASNLYESECMNETEWTIYQDWHDWMNNQFGQSLELDGIIYLQA
TPETCLHRIYLRGRNEEQGIPLEYLEKLHYKHESWLLHRTLKTNFDYLQEVPILTLDVNE
DFKDKYESLVEKVKEFLSTL

# Phase_1_Metabolizing_Enzyme_4_SwissProt_ID:
P27707

# Phase_1_Metabolizing_Enzyme_5_Gene_Name:
Not Available

# Phase_1_Metabolizing_Enzyme_5_ID:
7250

# Phase_1_Metabolizing_Enzyme_5_Name:
Deoxycytidylate deaminase

# Phase_1_Metabolizing_Enzyme_5_Protein_Sequence:
Not Available

# Phase_1_Metabolizing_Enzyme_5_SwissProt_ID:
P32321

# Drug_Target_1_Cellular_Location:
Nucleus and mitochondria

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10037146	Foti M, Omichinski JG, Stahl S, Maloney D, West J, Schweitzer BI: Effects of nucleoside analog incorporation on DNA binding to the DNA binding domain of the GATA-1 erythroid transcription factor. FEBS Lett. 1999 Feb 5;444(1):47-53.
20459144	Prakasha Gowda AS, Polizzi JM, Eckert KA, Spratt TE: Incorporation of gemcitabine and cytarabine into DNA by DNA polymerase beta and ligase III/XRCC1. Biochemistry. 2010 Jun 15;49(23):4833-40.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
>Example: Dickerson dodecamer
CGCGAATTCGCG

# Drug_Target_1_General_Function:
Biological information storage and information transfer

# Drug_Target_1_General_References:
1234	Nadeau D, Marchand C: Change in the kinetics of sulphacetamide tissue distribution in Walker tumor-bearing rats. Drug Metab Dispos. 1975 Nov-Dec;3(6):565-76.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
874

# Drug_Target_1_Locus:
All loci

# Drug_Target_1_Molecular_Weight:
7656 (double strand)

# Drug_Target_1_Name:
DNA

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
1BNA

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
DNA + DNA polymerase + nNTP = 2 DNA + nNDP; DNA + RNA polymerase + NTP = mRNA + nNDP

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.

# Drug_Target_1_SwissProt_ID:
Not Available

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
Deoxyribonucleic acid

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Nucleus

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
15011952	Miura S, Izuta S: DNA polymerases as targets of anticancer nucleosides. Curr Drug Targets. 2004 Feb;5(2):191-5.
16866189	Angeli JP, Ribeiro LR, Bellini MF, Mantovanil: Anti-clastogenic effect of beta-glucan extracted from barley towards chemically induced DNA damage in rodent cells. Hum Exp Toxicol. 2006 Jun;25(6):319-24.
19372559	Krynetskaia NF, Phadke MS, Jadhav SH, Krynetskiy EY: Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 2009 Apr;8(4):864-72.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
POLB

# Drug_Target_2_GenBank_ID_Gene:
L11607

# Drug_Target_2_GenBank_ID_Protein:
292397

# Drug_Target_2_GeneCard_ID:
POLB

# Drug_Target_2_Gene_Name:
POLB

# Drug_Target_2_Gene_Sequence:
>1008 bp
ATGAGCAAACGGAAGGCGCCGCAGGAGACTCTCAACGGGGGAATCACCGACATGCTCACA
GAACTCGCAAACTTTGAGAAGAACGTGAGCCAAGCTATCCACAAGTACAATGCTTACAGA
AAAGCAGCATCTGTTATAGCAAAATACCCACACAAAATAAAGAGTGGAGCTGAAGCTAAG
AAATTGCCTGGAGTAGGAACAAAAATTGCTGAAAAGATTGATGAGTTTTTAGCAACTGGA
AAATTACGTAAACTGGAAAAGATTCGGCAGGATGATACGAGTTCATCCATCAATTTCCTG
ACTCGAGTTAGTGGCATTGGTCCATCTGCTGCAAGGAAGTTTGTAGATGAAGGAATTAAA
ACACTAGAAGATCTCAGAAAAAATGAAGATAAATTGAACCATCATCAGCGAATTGGGCTG
AAATATTTTGGGGACTTTGAAAAAAGAATTCCTCGTGAAGAGATGTTACAAATGCAAGAT
ATTGTACTAAATGAAGTTAAAAAAGTGGATTCTGAATACATTGCTACAGTCTGTGGCAGT
TTCAGAAGAGGTGCAGAGTCCAGTGGTGACATGGATGTTCTCCTGACCCATCCCAGCTTC
ACTTCAGAATCAACCAAACAGCCAAAACTGTTACATCAGGTTGTGGAGCAGTTACAAAAG
GTTCATTTTATCACAGATACCCTGTCAAAGGGTGAGACAAAGTTCATGGGTGTTTGCCAG
CTTCCCAGTAAAAATGATGAAAAAGAATATCCACACAGAAGAATTGATATCAGGTTGATA
CCCAAAGATCAGTATTACTGTGGTGTTCTCTATTTCACTGGGAGTGATATTTTCAATAAG
AATATGAGGGCTCATGCCCTAGAAAAGGGTTTCACAATCAATGAGTACACCATCCGTCCC
TTGGGAGTCACTGGAGTTGCAGGAGAACCCCTGCCAGTGGATAGTGAAAAAGACATCTTT
GATTACATCCAGTGGAAATACCGGGAACCCAAGGACCGGAGCGAATGA

# Drug_Target_2_General_Function:
Replication, recombination and repair

# Drug_Target_2_General_References:
11805079	DeMott MS, Beyret E, Wong D, Bales BC, Hwang JT, Greenberg MM, Demple B: Covalent trapping of human DNA polymerase beta by the oxidative DNA lesion 2-deoxyribonolactone. J Biol Chem. 2002 Mar 8;277(10):7637-40. Epub 2002 Jan 22.
2423078	SenGupta DN, Zmudzka BZ, Kumar P, Cobianchi F, Skowronski J, Wilson SH: Sequence of human DNA polymerase beta mRNA obtained through cDNA cloning. Biochem Biophys Res Commun. 1986 Apr 14;136(1):341-7.
3182828	Widen SG, Kedar P, Wilson SH: Human beta-polymerase gene. Structure of the 5'-flanking region and active promoter. J Biol Chem. 1988 Nov 15;263(32):16992-8.
3284575	Abbotts J, SenGupta DN, Zmudzka B, Widen SG, Notario V, Wilson SH: Expression of human DNA polymerase beta in Escherichia coli and characterization of the recombinant enzyme. Biochemistry. 1988 Feb 9;27(3):901-9.
7914364	Chyan YJ, Ackerman S, Shepherd NS, McBride OW, Widen SG, Wilson SH, Wood TG: The human DNA polymerase beta gene structure. Evidence of alternative splicing in gene expression. Nucleic Acids Res. 1994 Jul 25;22(14):2719-25.
8841119	Pelletier H, Sawaya MR, Wolfle W, Wilson SH, Kraut J: A structural basis for metal ion mutagenicity and nucleotide selectivity in human DNA polymerase beta. Biochemistry. 1996 Oct 1;35(39):12762-77.
8841120	Pelletier H, Sawaya MR: Characterization of the metal ion binding helix-hairpin-helix motifs in human DNA polymerase beta by X-ray structural analysis. Biochemistry. 1996 Oct 1;35(39):12778-87.
9287163	Sawaya MR, Prasad R, Wilson SH, Kraut J, Pelletier H: Crystal structures of human DNA polymerase beta complexed with gapped and nicked DNA: evidence for an induced fit mechanism. Biochemistry. 1997 Sep 16;36(37):11205-15.
9572863	Matsumoto Y, Kim K, Katz DS, Feng JA: Catalytic center of DNA polymerase beta for excision of deoxyribose phosphate groups. Biochemistry. 1998 May 5;37(18):6456-64.

# Drug_Target_2_HGNC_ID:
HGNC:9174

# Drug_Target_2_HPRD_ID:
07517

# Drug_Target_2_ID:
125

# Drug_Target_2_Locus:
8p11.2

# Drug_Target_2_Molecular_Weight:
38047

# Drug_Target_2_Name:
DNA polymerase beta

# Drug_Target_2_Number_of_Residues:
334

# Drug_Target_2_PDB_ID:
8ICK

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
>DNA polymerase beta
SKRKAPQETLNGGITDMLTELANFEKNVSQAIHKYNAYRKAASVIAKYPHKIKSGAEAKK
LPGVGTKIAEKIDEFLATGKLRKLEKIRQDDTSSSINFLTRVSGIGPSAARKFVDEGIKT
LEDLRKNEDKLNHHQRIGLKYFGDFEKRIPREEMLQMQDIVLNEVKKVDSEYIATVCGSF
RRGAESSGDMDVLLTHPSFTSESTKQPKLLHQVVEQLQKVHFITDTLSKGETKFMGVCQL
PSKNDEKEYPHRRIDIRLIPKDQYYCGVLYFTGSDIFNKNMRAHALEKGFTINEYTIRPL
GVTGVAGEPLPVDSEKDIFDYIQWKYREPKDRSE

# Drug_Target_2_Reaction:
deoxynucleoside triphosphate + DNAn = diphosphate + DNAn+1

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Repair polymerase. Conducts "gap-filling" DNA synthesis in a stepwise distributive fashion rather than in a processive fashion as for other DNA polymerases. Has a 5'-deoxyribose-5- phosphate lyase (dRP lyase) activity

# Drug_Target_2_SwissProt_ID:
P06746

# Drug_Target_2_SwissProt_Name:
DPOLB_HUMAN

# Drug_Target_2_Synonyms:
EC 2.7.7.7
EC 4.2.99.-

# Drug_Target_2_Theoretical_pI:
9.41

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB00987
